Quintessence Publishing: Events

Share Page:


Thursday, June 6
Friday, June 7
Saturday, June 8
Sunday, June 9

Session III: Defining and Implementing “Definitive” Periodontal and Peri-Implant Treatment in Specific Patient Groups: Critical Advances for the Practicing Clinician


Lessons Learned about “Definitive” Periodontal Disease Treatment from Human Clinical Trials


Steven Offenbacher
Thursday, June 6
9:15 am - 10:15 am
Grand Ballroom (Salon A-D)

The concept that periodontal disease represents an independent factor that potentially worsens systemic conditions remains controversial. Although most meta-analysis studies continue to show associations with certain conditions such as diabetes, randomized controlled clinical trials (RCTs) on diseased populations have generally failed to show a consistent impact on systemic conditions, rather demonstrating secondary effects of periodontal therapy on surrogate endpoints or risk factors. Unfortunately, because RCTs are considered the current “gold standard” for proving drug efficacy claims for FDA clearance and public health adoption, the model has been perhaps inappropriately applied and interpreted in dentistry. In recent years, there has been significant departure in the public health strategy for drug clearance. Genomic testing and the use of biomarkers and other diagnostics refine the targeted population for therapy, leading to personalized, or targeted, medicine. Significant strides have been made in our understanding of the underlying genetic basis of periodontal disease and the recognition of biologic heterogeneity among patients with similar clinical signs and symptoms. This session will summarize the current knowledge and limitations associated with study design that impact the generalizability of the conclusions, and it will focus on the clinical relevance of these findings and how these apply to our understanding of the oral-systemic relationship. Approaches to treatment that are designed to reduce systemic risk will be discussed.


Steven Offenbacher, DDS, PhD, MMSc, received his DDS and PhD from Virginia Commonwealth University. He joined the department of Periodontology at the University of North Carolina (UNC) School of Dentistry in Chapel Hill in 1991. In 2003, he was appointed the OraPharma Distinguished Professor of Periodontal Medicine. In 2010, he was elected chairman of the Department of Periodontology at UNC School of Dentistry in Chapel Hill. He is the former president of the American Association of Dental Research and has served on the editorial board of several wellknown journals. He has published more than 300 papers, articles, book chapters, and manuscripts. Dr Offenbacher has earned many distinctions, including the Basic Research in Periodontal Disease Award from the International Association for Dental Research. He is the first dental scientist to be awarded the prestigious Healthy Mothers, Healthy Babies Special Impact Award.